Associate
Kathryn has particular experience representing pharmaceutical patent holders in litigations arising from ANDA matters under the Hatch-Waxman Act. Her practice also extends to trademark prosecution and litigation and design patents.
While completing her undergraduate degree, Kathryn shadowed as a biomedical student at a nonprofit cancer treatment and research center, where she studied gastrointestinal oncology and pathology. After deciding against attending medical school, Kathryn switched her biological science major to environmental science.
While in law school, Kathryn served as president of the Intellectual Property Law Society. She was a member of the Journal of Transnational Law and Policy as well as Business Review. She received a business law certificate with a focus on intellectual property law. Kathryn also worked as a summer associate at Finnegan.
Kathryn's pro bono practice includes representing disabled veterans in proceedings before the U.S. Court of Appeals for Veterans Claims and working with nonprofit organizations in Atlanta on trademark matters. She is recognized on the Capital Pro Bono Honor Roll.
Vifor (International) AG and American Regent, Inc. v. Mylan Labs. Ltd. et al.
Represented Vifor and American Regent in two Hatch-Waxman Act cases against Mylan and Sandoz regarding their attempts to obtain FDA approval for their respective ANDAs directed to generic copies of Injectafer®. After a six-day bench trial, the cases resulted in a favorable settlement for our clients with a generic entry date well past the expiration of the composition patents.
3:19-cv-13955, 3:19-cv-16305, D.N.J., Judges Wolfson, Arpert
Novartis Pharmaceuticals Corporation et al. v. Fresenius Kabi USA, LLC et al.
1:21-cv-00870, D. Del., Judge Hall
Kaken Pharmaceutical Co., Ltd.; Bausch Health Care v. Zydus Pharmaceuticals (USA) Inc. et al.
Successfully led Kaken and Bausch Health Care in inter partes review (IPR) proceedings, district court litigation, and Federal Circuit appeal related to patent covering Kaken and Bausch Health Care’s Jublia® (efinaconazole) product for the treatment of onychomycosis.
3:18-cv-13635, D.N.J., Judges Martinotti, Goodman
18-2232, Fed. Cir., Judges Newman, O'Malley, Taranto
IPR2017-00190, PTAB, Judges Mitchell, Franklin, Pollock
IPR2017-01429, PTAB, Judges Mitchell, Franklin, Pollock
American Regent, Inc. v. Pharmacosmos Therapeutics Inc. et al.
3:20-cv-01350, D.N.J., Judges Goodman, Martinotti, Quraishi
PGR2020-00009, PTAB, Judges Tornquist, Franklin, Wisz
Bial - Portela & CA S.A. v. Alkem Laboratories Ltd et al.
Representing Bial in district court Hatch-Waxman litigation involving the anti-epileptic drug Aptiom®.
1:18-cv-00304, D. Del., Judges Connolly, Burke
IP Health Blog
FDA Draft Guidance on Evaluation of Therapeutic Equivalence FDA Draft Guidance on Evaluation of Therapeutic Equivalence
August 4, 2022
IP Health Blog
Final FDA Guidance on Safety Considerations for Medication Container Labels and Carton Labeling Final FDA Guidance on Safety Considerations for Medication Container Labels and Carton Labeling
June 10, 2022
Books
Intellectual Property in the Energy Sector: Challenges and Opportunities for an Industry in Transition Intellectual Property in the Energy Sector: Challenges and Opportunities for an Industry in Transition
June 2022
Globe Law and BusinessEvent
Patent Inventorship: Best Practices for Determination and Correction Patent Inventorship: Best Practices for Determination and Correction
May 5, 2022
Articles
Driving Forward: The Automotive Tech Fuelling IP Interests Driving Forward: The Automotive Tech Fuelling IP Interests
April 5, 2022
Managing Intellectual PropertyPress Release
46 Finnegan Attorneys Named to 2021 Capital Pro Bono Honor Roll 46 Finnegan Attorneys Named to 2021 Capital Pro Bono Honor Roll
June 3, 2022
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.